Synthesis and Characterization
of Urofuranoic Acids:
In Vivo Metabolism of 2‑(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic
Acid (CMPF) and Effects on in Vitro Insulin Secretion
posted on 2017-02-07, 00:00authored byEdith Nagy, Ying Liu, Kacey J. Prentice, Kyle W. Sloop, Phillip E. Sanders, Battsetseg Batchuluun, Craig D. Hammond, Michael B. Wheeler, Timothy B. Durham
CMPF (2-(2-carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic
acid)
is a metabolite that circulates at high concentrations in type 2 and
gestational diabetes patients. Further, human clinical studies suggest
it might have a causal role in these diseases. CMPF inhibits insulin
secretion in mouse and human islets in vitro and in vivo in rodents.
However, the metabolic fate of CMPF and the
relationship of structure to effects on insulin secretion have not
been significantly studied. The syntheses of CMPF and analogues are
described. These include isotopically labeled molecules. Study of
these materials in vivo has led to the first observation of a metabolite
of CMPF. In addition, a wide range of CMPF analogues have been prepared
and characterized in insulin secretion assays using both mouse and
human islets. Several molecules that influence insulin secretion in
vitro were identified. The molecules described should serve as interesting
probes to further study the biology of CMPF.